Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 890 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo device Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Medicinal Nicotine for Preventing Cue Induced Craving

NCT02347605
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine lozenge 4 mg, Placebo lozenge
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 20, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
16
States / cities
Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

NCT04669665
View directory record Official record
Conditions
Depressive Disorder, Major, Suicidal
Interventions
SLS-002, Placebo, Standard of care, Intranasal device
Drug · Other · Device
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Orange, California • Panorama City, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intracervical Lidocaine Gel for IUD Insertional Pain

NCT01214161
View directory record Official record
Conditions
Pain
Interventions
2% lidocaine gel, placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One-Year Study

NCT00168844
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Inhalation Solution, Placebo
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
983 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 20, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

NCT03594175
View directory record Official record
Conditions
Catheter Occlusion, Thrombosis
Interventions
CUSA-081, Placebo, Alteplase
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Treatment of Emotional Dysfunction in Post Traumatic Stress Disorder (PTSD)

NCT01391832
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS), Cognitive Processing Therapy, Repetitive Transcranial Magnet Stimulation (rTMS)
Device · Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 60 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 20, 2026, 5:47 PM EDT
Recruiting Not applicable Interventional

The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and Fibromyalgia

NCT07841509
View directory record Official record
Conditions
Migraine, Fibromyalgia, Conditioned Pain Modulation
Interventions
Remote Electrical Neuromodulation (REN) device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BRIDGE Percutaneous Nerve Stimulation for Cesarean Delivery Pain Control

NCT04365465
View directory record Official record
Conditions
Opioid-use Disorder, Pain, Postoperative
Interventions
NSS-2 Bridge, Inactive NSS-2 Bridge, Active control
Device · Other
Lead sponsor
Grace Lim, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 20, 2026, 5:47 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking

NCT05665465
View directory record Official record
Conditions
Adverse Childhood Experiences, Nicotine Dependence, Cigarettes
Interventions
Nicotine nasal spray 0.5 mg, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

NCT02404532
View directory record Official record
Conditions
Device Latency
Interventions
MIND1 System
Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 20, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD

NCT00927784
View directory record Official record
Conditions
Heart Failure
Interventions
Mesenchymal Precursor cells (RevascorTM), Cryoprotective media alone
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
San Diego, California • Washington D.C., District of Columbia • Oak Lawn, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

Meibomian Gland Dysfunction Treatment

NCT04229888
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
LipiFlow, Light Based (Sham) Treatment
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women

NCT01534520
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

NCT02395042
View directory record Official record
Conditions
Cystitis, Interstitial, Ulcer
Interventions
LiRIS®, LiRIS Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Murrieta, California • Vacaville, California • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Acute Treatment Trial in Adult Subjects With Migraines

NCT03872453
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
82
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

NCT01457781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
16 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

NCT01533519
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Neuropeptide Y
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Not applicable Interventional Results available

A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence

NCT02160314
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
pessary, Absorbent pad
Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 20, 2026, 5:47 PM EDT
Recruiting Not applicable Interventional

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

NCT06182397
View directory record Official record
Conditions
Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions
MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
21 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 20, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

NCT02682225
View directory record Official record
Conditions
Drug Abuse
Interventions
Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 20, 2026, 5:47 PM EDT